Ebumab is a biotechnology research company utilizing AMT technology in combination with the body’s own immune system to fight cancer.
Ebumab has raised $495K in total funding. The most recent round was Convertible Note. The last funding was announced in September 2022.
Ebumab's investors include BioInnovation Institute.
Ebumab is headquartered in Copenhagen, Denmark.
Ebumab is a biotechnology research company utilizing AMT technology in combination with the body’s own immune system to fight cancer.
Ebumab is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ebumab — Funding & Investors." VCBacked, September 6, 2022, https://www.vcbacked.co/company/ebumab. Accessed August 14, 2026.
VCBacked. (2022). Ebumab — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/ebumab
{{cite web |title=Ebumab — Funding & Investors |url=https://www.vcbacked.co/company/ebumab |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated